
Requiring Humira Biosimilars Results in Huge Savings for Navitus Clients
Commercial clients of Navitus Health Solutions saw a 60% reduction in net cost per claim after the PBM removed the arthritis drug Humira (adalimumab) from its formularies in favor of three biosimilar options. Navitus is forecasting annualized net savings …